Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : – Share repurchase programme

06/07/2021 | 07:47am EDT

Bagsværd, Denmark, 7 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 7 May 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 10 May 2021 to 3 August 2021.

Since the announcement as of 31 May 2021, the following transactions have been made:

 Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement1,416,917 684,439,606
31 May 2021110,000483.0353,132,991
1 June 2021110,000485.1153,361,885
2 June 2021110,000482.4553,069,957
3 June 2021110,000482.0553,025,546
4 June 2021110,000488.4053,724,229
Accumulated under the programme1,966,917 950,754,213

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 13,170,192 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12-month period beginning 3 February 2021. As of 4 June 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 14,331,694 B shares at an average share price of DKK 456.13 per B share equal to a transaction value of DKK 6,537,113,462.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:  
Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.com
Michael Bachner (US)+1 609 664 7308mzyb@novonordisk.com
   
Investors:  
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
David Heiberg Landsted+45 3077 6915dhel@novonordisk.com
Mark Joseph Root (US)+1 848 213 3219mjhr@novonordisk.com

Company announcement No 39/2021

Attachment

  • CA_210607_SafeHarbour

© OMX, source GlobeNewswire - EU Press Releases

All news about NOVO NORDISK A/S
12:08pEUROPE : European shares notch fourth straight record high on earnings strength
RE
12:08pEUROPE : European shares notch fourth straight record high on earnings strength
RE
11:08aEuropean ADRs Move Higher in Thursday Trading
MT
06:15aNOVO NORDISK A/S : CEO Says Pandemic Boosting Sales of Obesity Drug
MT
04:19aWorld stocks off record peak, dollar up on hawkish Fed official
RE
03:26aNOVO NORDISK : Barclays reiterates its Buy rating
MD
02:37aNOVO NORDISK : Gets a Buy rating from JP Morgan
MD
12:17aNovo Nordisk Raises 2021 Guidance After Forecast-Beating 2Q Earnings
DJ
08/04NOVO NORDISK : Goldman Sachs reiterates its Buy rating
MD
08/04NOVO NORDISK : Receives a Buy rating from JP Morgan
MD
More news
Financials
Sales 2021 135 B 21 527 M 21 527 M
Net income 2021 45 502 M 7 235 M 7 235 M
Net cash 2021 6 594 M 1 048 M 1 048 M
P/E ratio 2021 32,1x
Yield 2021 1,54%
Capitalization 1 473 B 235 B 234 B
EV / Sales 2021 10,8x
EV / Sales 2022 9,97x
Nbr of Employees 45 157
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Last Close Price 642,70 DKK
Average target price 533,63 DKK
Spread / Average Target -17,0%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S43.21%222 926
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613